Eckert & Ziegler Strahlen- und Medizintechnik Stock
Eckert & Ziegler Strahlen- und Medizintechnik Stock price
Key metrics
Is Eckert & Ziegler Strahlen- und Medizintechnik a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 7,020 stocks worldwide.
Eckert & Ziegler Strahlen- und Medizintechnik Stock Analysis
Analyst Opinions
6 Analysts have issued a Eckert & Ziegler Strahlen- und Medizintechnik forecast:
Analyst Opinions
6 Analysts have issued a Eckert & Ziegler Strahlen- und Medizintechnik forecast:
Financial data from Eckert & Ziegler Strahlen- und Medizintechnik
| Mar '25 |
+/-
%
|
||
| Revenue | 296 296 |
16%
16%
|
|
| Gross Profit | 142 142 |
15%
15%
|
|
| EBITDA | 82 82 |
26%
26%
|
EBIT (Operating Income) EBIT | 63 63 |
22%
22%
|
| Net Profit | 34 34 |
15%
15%
|
|
In millions EUR.
Don't miss a Thing! We will send you all news about Eckert & Ziegler Strahlen- und Medizintechnik directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Eckert & Ziegler Strahlen- und Medizintechnik Stock News
Company Profile
Eckert & Ziegler Strahlen- und Medizintechnik AG engages in the provision of isotope technology for medical, scientific, and industrial use. It operates through the following segments: Radiation Therapy, Isotope Products, and Radiopharma. The Radiation Therapy segment includes the production and distribution of medical products for the treatment of cancer using brachytherapy. The Isotope Products segment manufactures and distributes sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration and environmental monitoring sources and solutions, as well as bulk radioisotopes for pharmaceutical, therapeutic and industrial product manufacturers. The Radiopharma segment is specialized in the field of molecular imaging and nuclear medicine, supplying different radiopharmaceuticals, radiochemicals and related equipment for the synthesis and radiochromatography of PET/SPECT tracers and other radioisotopes. The company was founded by Andreas Eckert in 1997 and is headquartered in Berlin, Germany.
| Head office | Germany |
| CEO | Harald Hasselmann |
| Employees | 1,085 |
| Founded | 1997 |
| Website | www.ezag.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
